Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 443-451

  Hus, Iwona ^a   Kawaik, Jerzy ^b   Tabarkiewicz, Jacek ^a   Radej, Sebastian ^a   Hoser, Grazyna ^b   Bojarska Junak, Agnieszka ^a   Schmitt, Michael ^c   Giannopoulos, Krzysztof ^a   Dmoszynska, Anna ^a   Rolinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

B cell chronic lymphocytic leukemia; Immunotherapy; Irradiated leukemic cells

Indexed keywords

BCG VACCINE; CANCER VACCINE; CD38 ANTIGEN; PERIPHERAL BLOOD AUTOLOGOUS LEUKEMIC CELL VACCINE; PROTEIN KINASE ZAP 70;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; BONE PAIN; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CD3+ CD24+ T LYMPHOCYTE; CD3+ CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE ULCER; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD; APOPTOSIS; BCG VACCINE; CANCER VACCINES; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHAGOCYTOSIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 48749122626     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000027     Document Type: Article

References (27)

1. Kipps TJ: Chronic lymphocytic leukemia. Curr Opin Hematol 7: 223-234, 2000.
2. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338: 1506-1514, 1998.
3. Shanafelt TD and Call TG: Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 79: 388-398, 2004.
4. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C and Czuczman MS: A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 41: 77-87, 2001.
5. Schmidt SM, Schag K, Muller MR, et al: Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102: 571-576, 2003.
6. Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, and Wendtner CM: Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105: 1566-1573, 2005.
7. Giannopoulos K, Li L, Bojarska-Junak A, et al: Expression of RHAMM/ CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 29: 95-103, 2006.
8. Morales A, Eidinger D and Bruce AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.
9. Brandau S and Suttmann H: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61: 299-305, 2007.
10. Vermorken JB, Claessen AM, van Tinteren H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353: 345-350, 1999.
11. Hus I, Podhorecka M, Bojarska-Junak A, et al: The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 17: 683-690, 2006.
12. Bojarska-Junak A, Giannopoulos K, Kowal M, Dmoszynska A and Rolinski J: Comparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin Cytom 70: 293-301, 2006.
13. Crespo M, Bosch F and Villamor N: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukaemia. N Engl J Med 348: 1764-1775, 2003.
14. Gricks CS, Zahrieh D, Zauls AJ, et al: Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104: 4002-4009, 2004.
15. Giannopoulos K, Dmoszynska A, Rolinski J, Hus I and Schmitt M: The expression of survivin in patients with B-cell chronic lymphocytic leukemia (B-CLL). Acta Haemat Pol 36: 83-88, 2005.
16. McCune CS, O'Donnell RW, Marquis DM and Sahasrabudhe DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32: 62-66, 1990.
17. Lotem M, Peretz T, Drize O, et al: Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer 86: 1534-1539, 2002.
18. Hoover HC Jr, Brandhorst JS, Peters LC, et al: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11: 390-399, 1993.
19. Hanna MC Jr and Peters LC: Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 42: 2613-2625, 1978.
20. Robinson MR: The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United Kingdom. Prog Clin Biol Res 310: 147-151, 1989.
21. Wierda WG, Kipps TJ and Keating MJ: Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23: 6325-6332, 2005.
22. Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K and Spaner DE: Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 9: 1656-1665, 2003.
23. Ravandi F and O'Brien S: Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 55: 197-209, 2006.
24. Kay NE, Hamblin TJ, Jelinek DF, et al: Chronic lymphocytic leukemia. Hematology 2002: 193-213, 2002.
25. Shimoni A, Marcus H, Canaan A, Ergas D, David M, Berrebi A and Reisner Y: A model for human B-chronic lymphocytic leukemia in human/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood 89: 2210-2218, 1997.
26. Spaner DE, Hammond C, Mena J, Foden C and Deabreu A: A phase I/II trial of oxidized autologous tumor vaccines during the 'watch and wait' phase of chronic lymphocytic leukemia. Cancer Immunol Immunother 54: 635-646, 2005.
27. Biagi E, Rousseau R, Yvon E, et al: Responses to human CD40 ligand/ human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11: 6916-6923, 2005.